TSHA · Nasdaq · CIK 0001806310

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Aug 14, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $9.8M and net income of -$109.0M, according to its XBRL data on EDGAR. Its EDGAR record lists 14 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$9.8M
Net income, FY2025
-$109.0M
Form 4 filings on record, past 12 months
14

Company overview

Legal name (as filed)
Taysha Gene Therapies, Inc.
Ticker
TSHA
SEC Central Index Key (CIK)
0001806310
Business address
DALLAS, TX
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2261 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Taysha Gene Therapies, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021$2.5MFY2022$15.5MFY2023$8.3MFY2024$9.8MFY2025
Net income
-$174.5MFY2021-$166.0MFY2022-$111.6MFY2023-$89.3MFY2024-$109.0MFY2025
TSHA annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—$2.5M$15.5M$8.3M$9.8M
Net income-$174.5M-$166.0M-$111.6M-$89.3M-$109.0M
Diluted EPS-$4.64-$3.78-$0.96-$0.36-$0.34
Total assets$214.0M$126.3M$172.7M$160.4M$343.3M
Cash and equivalents$149.1M$87.9M$143.9M$139.0M$319.8M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

TSHA latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 19, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 20268-KResults of operations· period Aug 11, 2026Document · Index
Apr 22, 2026DEF 14ADefinitive proxy statement· period Jun 1, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Taysha Gene Therapies, Inc., by form type:

4 ×10144 ×9SCHEDULE 13G/A ×68-K ×610-Q ×2424B5 ×2ARS ×1DEFA14A ×1DEF 14A ×110-K ×1SCHEDULE 13G ×1
TSHA recent filings
FiledFormWhat it isOriginal
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 20268-KResults of operations· period Aug 11, 2026Document · Index
Jul 10, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 10, 2026Document · Index
Jun 25, 20268-KMaterial agreement; Other events· period Jun 24, 2026Document · Index
Jun 25, 2026424B5424B5Document · Index
Jun 24, 2026424B5424B5Document · Index
Jun 22, 20268-KRegulation FD disclosure; Other events· period Jun 22, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 2, 20268-KShareholder vote results· period Jun 1, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 6, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 6, 20268-KResults of operations· period May 6, 2026Document · Index
Apr 22, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 22, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 22, 2026DEF 14ADefinitive proxy statement· period Jun 1, 2026Document · Index
Apr 13, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 10, 2026Document · Index
Apr 10, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 19, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 19, 20268-KResults of operations· period Mar 19, 2026Document · Index
Feb 27, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 17, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Feb 6, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 4, 2026Document · Index
Feb 5, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 4, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 4, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 4, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 4, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 4, 2026144Notice of proposed sale of securitiesDocument · Index
Jan 27, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 23, 2026Document · Index
Jan 27, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 23, 2026Document · Index
Jan 27, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 23, 2026Document · Index
Jan 23, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

14 Form 4 filings appear in Taysha Gene Therapies, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in Texas

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001806310 and XBRL company facts. Taysha Gene Therapies, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.